0001919246-26-000070
SEC filingPelthos reported $10.9M in Q1 FY2026 revenue from ZELSUVMI commercial sales, but incurred a $10.2M net loss and $13.1M net cash outflow from operations — reflecting the expected investment phase as the company scales infrastructure and commercial execution while maintaining strong gross margin leverage.
Revenue of $10.9 million for the quarter ended March 31, 2026 represents the first full quarter of commercial sales for ZELSUVMI following its July 2025 launch. This revenue stream reflects demand fulfillment through the Company’s wholesale channel — where wholesalers purchase products and supply retail drug store chains, independent pharmacies, and mail order pharmacies — and does not include material contributions from XEPI or XEGLYZE, consistent with their respective development and commercial timelines.
Gross profit totaled $9.2 million, yielding a gross margin of 84.7%. This high margin reflects the efficiency of Pelthos’ internal API manufacturing infrastructure. Management confirms the Company ‘currently has sufficient API manufacturing capacity within its facility, as it is configured, to comfortably meet its current sales forecasts to supply API for ZELSUVMI,’ and further notes it has ‘excess capacity to increase utilization for additional API demand.’ These statements directly support the sustainability and scalability of the current gross margin profile without requiring new capital investment in production capacity.
Operating income was -$13.1 million, a significant decline from -$1.8 million in Q1 FY2025. This widening reflects deliberate investment in commercial infrastructure, including manufacturing overhead, third-party logistics, distribution, quality control, and freight — all categorized as cost of goods sold per management’s description of fulfillment-related expenses. The year-over-year deterioration is not attributable to pricing pressure or volume shortfall, but to the structural costs of standing up a commercial organization and fulfilling customer orders at scale.
Net cash used in operating activities was -$13.1 million, and after $194,000 in capital expenditures, free cash flow totaled -$13.3 million. This outflow reflects the typical timing lag in biopharma commercialization: revenue is recognized upon shipment to wholesalers, while gross-to-net deductions, royalty obligations, and other accruals settle later. Management observes that ‘while risks remain, available liquidity and cash generation from operations are sufficient for near-term needs,’ affirming the current cash burn is operationally intentional and aligned with the commercial ramp plan. The Company anticipates future cash use will primarily fund operations, working capital, capital expenditures, and general corporate purposes — consistent with its stated capital requirements.